Mary Nilsson

1.7k total citations
29 papers, 1.1k citations indexed

About

Mary Nilsson is a scholar working on Pharmacology, Clinical Psychology and Psychiatry and Mental health. According to data from OpenAlex, Mary Nilsson has authored 29 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pharmacology, 9 papers in Clinical Psychology and 9 papers in Psychiatry and Mental health. Recurrent topics in Mary Nilsson's work include Treatment of Major Depression (8 papers), Attention Deficit Hyperactivity Disorder (7 papers) and Child and Adolescent Psychosocial and Emotional Development (7 papers). Mary Nilsson is often cited by papers focused on Treatment of Major Depression (8 papers), Attention Deficit Hyperactivity Disorder (7 papers) and Child and Adolescent Psychosocial and Emotional Development (7 papers). Mary Nilsson collaborates with scholars based in United States, Denmark and Austria. Mary Nilsson's co-authors include S. Hoog, John H. Heiligenstein, Graham J. Emslie, Jennie G. Jacobson, Karen Dineen Wagner, Eileen Brown, Jill Gonzales, Stephanie C. Koke, Charles M. Beasley and Maurizio Fava and has published in prestigious journals such as Gut, Biological Psychiatry and Journal of the American Academy of Child & Adolescent Psychiatry.

In The Last Decade

Mary Nilsson

29 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mary Nilsson United States 15 547 539 352 238 141 29 1.1k
Darlene H. Moak United States 19 299 0.5× 409 0.8× 243 0.7× 285 1.2× 150 1.1× 26 2.0k
Kristina Fritz Australia 17 638 1.2× 281 0.5× 288 0.8× 202 0.8× 136 1.0× 34 1.2k
Gianluca Rosso Italy 22 519 0.9× 537 1.0× 285 0.8× 268 1.1× 107 0.8× 86 1.4k
J M Perel United States 21 433 0.8× 450 0.8× 331 0.9× 263 1.1× 161 1.1× 31 1.3k
Claudia F. Baldassano United States 20 1.0k 1.9× 299 0.6× 249 0.7× 151 0.6× 155 1.1× 33 1.4k
Andrew W. Brotman United States 21 700 1.3× 709 1.3× 206 0.6× 170 0.7× 95 0.7× 48 1.4k
Xavier Torres Spain 18 554 1.0× 287 0.5× 383 1.1× 105 0.4× 63 0.4× 40 1.1k
David J. Muzina United States 23 1.1k 1.9× 341 0.6× 402 1.1× 249 1.0× 62 0.4× 55 1.5k
John Tiller Australia 18 449 0.8× 287 0.5× 352 1.0× 212 0.9× 62 0.4× 56 1.1k
Claudio Mencacci Italy 17 436 0.8× 259 0.5× 159 0.5× 206 0.9× 70 0.5× 74 1.0k

Countries citing papers authored by Mary Nilsson

Since Specialization
Citations

This map shows the geographic impact of Mary Nilsson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Nilsson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Nilsson more than expected).

Fields of papers citing papers by Mary Nilsson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Nilsson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Nilsson. The network helps show where Mary Nilsson may publish in the future.

Co-authorship network of co-authors of Mary Nilsson

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Nilsson. A scholar is included among the top collaborators of Mary Nilsson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Nilsson. Mary Nilsson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nilsson, Mary, et al.. (2020). Clinical Trial Drug Safety Assessment With Interactive Visual Analytics. Statistics in Biopharmaceutical Research. 13(3). 355–366. 4 indexed citations
2.
Beasley, Charles M., Brenda Crowe, Mary Nilsson, et al.. (2017). Reference Limits for Outlier Analyses in Randomized Clinical Trials. Therapeutic Innovation & Regulatory Science. 51(6). 683–737. 1 indexed citations
3.
Nilsson, Mary, et al.. (2015). PWE-242 A novel mri-based method to assess human colon volume in experimental opioid-induced bowel dysfunction. Gut. 64(Suppl 1). A318.2–A319. 1 indexed citations
4.
Nilsson, Mary, Jakob Lykke Poulsen, Magnus Gram, et al.. (2015). Quantification and variability in colonic volume with a novel magnetic resonance imaging method. Neurogastroenterology & Motility. 27(12). 1755–1763. 28 indexed citations
5.
Nilsson, Mary, Thomas Nissen, Carina Graversen, et al.. (2013). Reproducibility of psychophysics and electroencephalography during offset analgesia. European Journal of Pain. 18(6). 824–834. 14 indexed citations
6.
Gassmann-Mayer, Cristiana, Kun Jiang, P. McSorley, et al.. (2011). Clinical and Statistical Assessment of Suicidal Ideation and Behavior in Pharmaceutical Trials. Clinical Pharmacology & Therapeutics. 90(4). 554–560. 15 indexed citations
7.
Tauscher‐Wisniewski, Sitra, Mary Nilsson, Cathy Caldwell, John M. Plewes, & Albert J. Allen. (2007). Meta-Analysis of Aggression and/or Hostility-Related Events in Children and Adolescents Treated with Fluoxetine Compared with Placebo. Journal of Child and Adolescent Psychopharmacology. 17(5). 713–718. 7 indexed citations
8.
Beasley, Charles M., Susan Ball, Mary Nilsson, et al.. (2007). Fluoxetine and Adult Suicidality Revisited. Journal of Clinical Psychopharmacology. 27(6). 682–686. 16 indexed citations
9.
Guo, Ying, Mary Nilsson, John H. Heiligenstein, Michael G. Wilson, & Graham J. Emslie. (2006). An Exploratory Factor Analysis of the Children’s Depression Rating Scale–Revised. Journal of Child and Adolescent Psychopharmacology. 16(4). 482–491. 27 indexed citations
10.
Heiligenstein, John H., S. Hoog, Karen Dineen Wagner, et al.. (2006). Fluoxetine 40–60 mg versus Fluoxetine 20 mg in the Treatment of Children and Adolescents with a Less-Than-Complete Response to Nine-Week Treatment with Fluoxetine 10–20 mg: APilot Study. Journal of Child and Adolescent Psychopharmacology. 16(1-2). 207–217. 22 indexed citations
11.
Nilsson, Mary, et al.. (2004). Safety of Subchronic Treatment with Fluoxetine for Major Depressive Disorder in Children and Adolescents. Journal of Child and Adolescent Psychopharmacology. 14(3). 412–417. 32 indexed citations
12.
Emslie, Graham J., John H. Heiligenstein, S. Hoog, et al.. (2004). Fluoxetine Treatment for Prevention of Relapse of Depression in Children and Adolescents: A Double-Blind, Placebo-Controlled Study. Journal of the American Academy of Child & Adolescent Psychiatry. 43(11). 1397–1405. 102 indexed citations
13.
Nilsson, Mary, et al.. (2004). Safety of Subchronic Treatment with Fluoxetine for Major Depressive Disorder in Children and Adolescents. Journal of Child and Adolescent Psychopharmacology. 14(3). 412–417. 2 indexed citations
14.
Emslie, Graham J., John H. Heiligenstein, Karen Dineen Wagner, et al.. (2002). Fluoxetine for Acute Treatment of Depression in Children and Adolescents: A Placebo-Controlled, Randomized Clinical Trial. Journal of the American Academy of Child & Adolescent Psychiatry. 41(10). 1205–1215. 427 indexed citations
15.
Fava, Maurizio, et al.. (2002). Acute Efficacy of Fluoxetine Versus Sertraline and Paroxetine in Major Depressive Disorder Including Effects of Baseline Insomnia. Journal of Clinical Psychopharmacology. 22(2). 137–147. 77 indexed citations
16.
Casper, Regina C., Gary D. Tollefson, & Mary Nilsson. (2001). No gender differences in placebo responses of patients with major depressive disorder. Biological Psychiatry. 49(2). 158–160. 31 indexed citations
17.
Nilsson, Mary & Stephanie C. Koke. (2001). Defining Treatment-Emergent Adverse Events with the Medical Dictionary for Regulatory Activities (MedDRA). Drug Information Journal. 35(4). 1289–1299. 18 indexed citations
18.
Fava, Maurizio, et al.. (2000). Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. Journal of Affective Disorders. 59(2). 119–126. 105 indexed citations
19.
Beasley, Charles M., Mary Nilsson, Stephanie C. Koke, & Jill Gonzales. (2000). Efficacy, Adverse Events, and Treatment Discontinuations in Fluoxetine Clinical Studies of Major Depression. The Journal of Clinical Psychiatry. 61(10). 722–728. 53 indexed citations
20.
Beasley, Charles M., Stephanie C. Koke, Mary Nilsson, & Jill Gonzales. (2000). Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: An updated meta-analysis. Clinical Therapeutics. 22(11). 1319–1330. 66 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Darlene H. Moak Breakdown of academic impact, for papers by Kristina Fritz Breakdown of academic impact, for papers by Gianluca Rosso Breakdown of academic impact, for papers by J M Perel Breakdown of academic impact, for papers by Claudia F. Baldassano Breakdown of academic impact, for papers by Andrew W. Brotman Breakdown of academic impact, for papers by Xavier Torres Breakdown of academic impact, for papers by David J. Muzina Breakdown of academic impact, for papers by John Tiller Breakdown of academic impact, for papers by Claudio Mencacci
Rankless by CCL
2026